These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37314987)

  • 1. S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.
    Švec X; Štorkánová H; Trinh-Minh T; Tran MC; Štorkánová L; Hulejová H; Oreská S; Heřmánková B; Bečvář R; Pavelka K; Vencovský J; Klingelhöfer J; Hussain RI; Hallén J; Šenolt L; Distler JHW; Tomčík M
    Rheumatology (Oxford); 2024 Mar; 63(3):817-825. PubMed ID: 37314987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.
    Trinh-Minh T; Györfi AH; Tomcik M; Tran-Manh C; Zhou X; Dickel N; Tümerdem BS; Kreuter A; Burmann SN; Borchert SV; Hussain RI; Hallén J; Klingelhöfer J; Kunz M; Distler JHW
    Arthritis Rheumatol; 2024 May; 76(5):783-795. PubMed ID: 38108109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.
    Grum-Schwensen B; Klingelhöfer J; Beck M; Bonefeld CM; Hamerlik P; Guldberg P; Grigorian M; Lukanidin E; Ambartsumian N
    BMC Cancer; 2015 Feb; 15():44. PubMed ID: 25884510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.
    Tomcik M; Palumbo-Zerr K; Zerr P; Avouac J; Dees C; Sumova B; Distler A; Beyer C; Cerezo LA; Becvar R; Distler O; Grigorian M; Schett G; Senolt L; Distler JH
    Ann Rheum Dis; 2015 Sep; 74(9):1748-55. PubMed ID: 24709861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.
    Desallais L; Avouac J; Fréchet M; Elhai M; Ratsimandresy R; Montes M; Mouhsine H; Do H; Zagury JF; Allanore Y
    Arthritis Res Ther; 2014 Jul; 16(4):R157. PubMed ID: 25059342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis.
    Avouac J; Elhai M; Tomcik M; Ruiz B; Friese M; Piedavent M; Colonna M; Bernhardt G; Kahan A; Chiocchia G; Distler JH; Allanore Y
    Ann Rheum Dis; 2013 Jun; 72(6):1089-98. PubMed ID: 23161903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin.
    Štorkánová H; Štorkánová L; Navrátilová A; Bečvář V; Hulejová H; Oreská S; Heřmánková B; Špiritović M; Bečvář R; Pavelka K; Vencovský J; Distler JHW; Šenolt L; Tomčík M
    Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34200311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-S100A4 monoclonal antibody treatment ameliorates experimental skin fibrosis and SSc-specific transcriptional signatures in human skin: Comment on the targeting S100A4 is helpful in SSc treatment by Trinh-Minh et al.
    Huang AF; Xu WD
    Arthritis Rheumatol; 2024 Jul; 76(7):1164-1165. PubMed ID: 38351303
    [No Abstract]   [Full Text] [Related]  

  • 12. Activation of pregnane X receptor inhibits experimental dermal fibrosis.
    Beyer C; Skapenko A; Distler A; Dees C; Reichert H; Munoz L; Leipe J; Schulze-Koops H; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2013 Apr; 72(4):621-5. PubMed ID: 23291432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
    Ohashi T; Yamamoto T
    Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
    Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
    Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis.
    Avouac J; Fürnrohr BG; Tomcik M; Palumbo K; Zerr P; Horn A; Dees C; Akhmetshina A; Beyer C; Distler O; Schett G; Allanore Y; Distler JH
    Arthritis Rheum; 2011 Mar; 63(3):800-9. PubMed ID: 21360510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baicalein alleviates fibrosis and inflammation in systemic sclerosis by regulating B-cell abnormalities.
    Peng B; Hu Q; He R; Hou H; Lian D; Chen Y; Li H; Song L; Gao Y; Chen T; Zhang G; Li J
    BMC Complement Med Ther; 2023 Feb; 23(1):62. PubMed ID: 36810081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
    Mor A; Segal Salto M; Katav A; Barashi N; Edelshtein V; Manetti M; Levi Y; George J; Matucci-Cerinic M
    Ann Rheum Dis; 2019 Sep; 78(9):1260-1268. PubMed ID: 31129606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis.
    Tomcik M; Zerr P; Pitkowski J; Palumbo-Zerr K; Avouac J; Distler O; Becvar R; Senolt L; Schett G; Distler JH
    Ann Rheum Dis; 2014 Jun; 73(6):1215-22. PubMed ID: 23661493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
    Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S
    Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.